Daytime sleepiness predicts inflammation and ambulatory blood pressure in sleep apnoea
ERJ Open Research, 2020
Pak V., Butts B., Hertzberg V., Collop N., Quyyumi A., Cox J., Rogers A., Dunbar S.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD Other Diseases & Syndromes | Pathophysiology | Plasma |  Olink Target 96 |
Abstract
Introduction
Sleepiness in obstructive sleep apnoea is associated with cardiovascular risk; however, the biological mechanisms are not known. This study explored whether those with subjective sleepiness have increased plasma tumour necrosis factor-related protein 1 (C1qTNF1), a novel adipose-derived hormone (adipokine), and 24-h ambulatory blood pressure (ABP) compared to those without sleepiness in newly diagnosed, treatment-naïve participants with obstructive sleep apnoea.
Methods
Overall, 94 participants were included in the analysis. Participants completed the Epworth Sleepiness Scale (ESS), 24-h ABP was monitored, and plasma C1qTNF1 was measured. Sleepy participants were defined as ESS≥10 and nonsleepy as ESS<10. Multiple linear regression was used to explore differences in C1qTNF1, and 24-h mean arterial pressure (MAP) between sleepy and nonsleepy participants, adjusting for age, sex, body mass index, apnoea–hypopnoea index, and smoking status.
Results
C1qTNF1 was significantly higher in sleepy participants (n=57) compared to nonsleepy participants (n=37) (β=0.41 NPX, 95% CI 0.02, 0.80; p=0.04). The 24-h MAP was significantly higher in sleepy participants compared to nonsleepy participants (β=4.06 mmHg, 95% CI 0.36, 7.77; p=0.03).
Conclusions
Our findings show that sleepiness is associated with inflammation and higher 24-h MAP in sleep apnoea.